Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers

Boron-containing compounds (BCCs) have been proposed for the treatment of diabetes and its complications. Recent studies have reported an improvement in the design and development of pharmaceutical formulations (often gels) containing boric acid applied to the foot ulcers of humans diagnosed with di...

Full description

Saved in:
Bibliographic Details
Main Authors: Marvin A. Soriano-Ursúa, Marlet Martínez-Archundia, Ahmet Kilic, Teresa Pérez-Capistran, Miriam A. Hernández-Zamora, Juan E. López-Ramos, Eunice D. Farfán-García
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Scientia Pharmaceutica
Subjects:
Online Access:https://www.mdpi.com/2218-0532/93/1/14
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849339595249942528
author Marvin A. Soriano-Ursúa
Marlet Martínez-Archundia
Ahmet Kilic
Teresa Pérez-Capistran
Miriam A. Hernández-Zamora
Juan E. López-Ramos
Eunice D. Farfán-García
author_facet Marvin A. Soriano-Ursúa
Marlet Martínez-Archundia
Ahmet Kilic
Teresa Pérez-Capistran
Miriam A. Hernández-Zamora
Juan E. López-Ramos
Eunice D. Farfán-García
author_sort Marvin A. Soriano-Ursúa
collection DOAJ
description Boron-containing compounds (BCCs) have been proposed for the treatment of diabetes and its complications. Recent studies have reported an improvement in the design and development of pharmaceutical formulations (often gels) containing boric acid applied to the foot ulcers of humans diagnosed with diabetes. The proposed mechanisms of action of boric acid include antimicrobial effects, the modulation of inflammation and metabolism, and the induction of cell differentiation. On the other hand, recent studies have suggested that boronic acids are potent antibacterial and antifungal compounds, effective modulators of inflammation, and inducers of vascular regeneration as well as inducers of healing, and they confer attractive properties such as adhesion, interaction, and the formation of complexes in formulations. Moreover, only a handful of studies conducted in animals have suggested the effective role of some BCCs as potent enhancers of wound healing, including their actions on induced and/or infected wounds in animals with disrupted metabolism. Also, it should be mentioned that no strong interactions between boric acid and the boronic acids present in formulations have been described. The developed combination could act as an additive and complementary therapy in the treatment of diabetic ulcers in humans. Further studies are required to support the hypothesis that this combination acts through diverse mechanisms to improve healing while avoiding or limiting a local or disseminated infection. Furthermore, the safety of BCCs used for foot ulcers should be established, as should the role of these formulations as a complementary therapy in current protocols for treating patients with diabetic foot ulcers.
format Article
id doaj-art-d2a930e22def44a4bcaf50dd5f234e49
institution Kabale University
issn 0036-8709
2218-0532
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Scientia Pharmaceutica
spelling doaj-art-d2a930e22def44a4bcaf50dd5f234e492025-08-20T03:44:05ZengMDPI AGScientia Pharmaceutica0036-87092218-05322025-03-019311410.3390/scipharm93010014Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot UlcersMarvin A. Soriano-Ursúa0Marlet Martínez-Archundia1Ahmet Kilic2Teresa Pérez-Capistran3Miriam A. Hernández-Zamora4Juan E. López-Ramos5Eunice D. Farfán-García6Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, México City 11340, MexicoEscuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, México City 11340, MexicoDepartment of Chemistry, Faculty of Arts and Science, Harran University, Sanliurfa 63200, TurkeyEscuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, México City 11340, MexicoEscuela Nacional de Ciencias Biológicas, Manuel Carpio y Plutarco Elías Calles s/n, Miguel Hidalgo, México City 11350, MexicoCentro de Estudios Científicos y Tecnológicos del IPN, No. 18. Boulevard El Bote s/n, Zacatecas 98160, MexicoEscuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, México City 11340, MexicoBoron-containing compounds (BCCs) have been proposed for the treatment of diabetes and its complications. Recent studies have reported an improvement in the design and development of pharmaceutical formulations (often gels) containing boric acid applied to the foot ulcers of humans diagnosed with diabetes. The proposed mechanisms of action of boric acid include antimicrobial effects, the modulation of inflammation and metabolism, and the induction of cell differentiation. On the other hand, recent studies have suggested that boronic acids are potent antibacterial and antifungal compounds, effective modulators of inflammation, and inducers of vascular regeneration as well as inducers of healing, and they confer attractive properties such as adhesion, interaction, and the formation of complexes in formulations. Moreover, only a handful of studies conducted in animals have suggested the effective role of some BCCs as potent enhancers of wound healing, including their actions on induced and/or infected wounds in animals with disrupted metabolism. Also, it should be mentioned that no strong interactions between boric acid and the boronic acids present in formulations have been described. The developed combination could act as an additive and complementary therapy in the treatment of diabetic ulcers in humans. Further studies are required to support the hypothesis that this combination acts through diverse mechanisms to improve healing while avoiding or limiting a local or disseminated infection. Furthermore, the safety of BCCs used for foot ulcers should be established, as should the role of these formulations as a complementary therapy in current protocols for treating patients with diabetic foot ulcers.https://www.mdpi.com/2218-0532/93/1/14boricboroniculcergelwound healinginflammation
spellingShingle Marvin A. Soriano-Ursúa
Marlet Martínez-Archundia
Ahmet Kilic
Teresa Pérez-Capistran
Miriam A. Hernández-Zamora
Juan E. López-Ramos
Eunice D. Farfán-García
Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers
Scientia Pharmaceutica
boric
boronic
ulcer
gel
wound healing
inflammation
title Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers
title_full Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers
title_fullStr Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers
title_full_unstemmed Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers
title_short Formulations with Boric Acid or Aryl-Organoboron Compounds for Treating Diabetic Foot Ulcers
title_sort formulations with boric acid or aryl organoboron compounds for treating diabetic foot ulcers
topic boric
boronic
ulcer
gel
wound healing
inflammation
url https://www.mdpi.com/2218-0532/93/1/14
work_keys_str_mv AT marvinasorianoursua formulationswithboricacidorarylorganoboroncompoundsfortreatingdiabeticfootulcers
AT marletmartinezarchundia formulationswithboricacidorarylorganoboroncompoundsfortreatingdiabeticfootulcers
AT ahmetkilic formulationswithboricacidorarylorganoboroncompoundsfortreatingdiabeticfootulcers
AT teresaperezcapistran formulationswithboricacidorarylorganoboroncompoundsfortreatingdiabeticfootulcers
AT miriamahernandezzamora formulationswithboricacidorarylorganoboroncompoundsfortreatingdiabeticfootulcers
AT juanelopezramos formulationswithboricacidorarylorganoboroncompoundsfortreatingdiabeticfootulcers
AT eunicedfarfangarcia formulationswithboricacidorarylorganoboroncompoundsfortreatingdiabeticfootulcers